Concern over COVID-19 stems not only from its high degree of virulence, but from its ability to continuously mutate and produce new variants. An effective vaccine can help slow the virus’ spread, but the question of how to deal with its continuous mutations is key.
Mass production of the most well-known novel coronavirus vaccines in production, including by AstraZeneca PLC, Moderna Inc and Pfizer Inc, has a high technological threshold, especially for those using messenger RNA (mRNA) technology, since manufacturers need to overcome the challenges of storage and transportation at ultra-low temperatures.
Founded in 2018, Ascendo Biotechnology Inc (先知生技) has a research and development team with 30 years of clinical drug research experience, focused on immune-related drug research.
Photo courtesy of Ascendo Biotechnology Inc
Using quantum mechanics technologies, Ascendo has developed a proprietary NanoCherubTM electric-kinetic nanocomplex antigen adjuvant and delivery platform, designed to rapidly respond to mutations without the challenges of ultra-low temperature storage and transportation, and to produce large quantities of vaccines quickly
‧ NanoCherubTM in the fight against COVID-19
Doctors and scientists have been racking their brains for a solution to the constantly mutating virus. Using quantum mechanics calculations, Ascendo can produce effective vaccines quickly, with a precise and flexible technology circumventing the need for the constant testing of more traditional approaches.
Last year, Ascendo started working with academic research institutions in Taiwan on developing a COVID-19 vaccine, for the first time using quantum mechanics technology to design a drug delivery system encapsulating antigens to form a positively charged nanocomplex, enabling immune cells to generate a strong and effective response to the NanoCherubTM Electric-Kinetic nanocomplex and achieving a balanced and robust Th1/Th2 immunity.
The ASD254 vaccine developed by Ascendo last year showed excellent results in animal studies using mice, which most closely replicate the symptoms of the novel coronavirus in humans.
All vaccinated animals received 100 percent immune protection when tested with the live virus. Ascendo soon plans to apply to the Food and Drug Administration for phase 1 human trials, hoping to enter mass production next year.
The drug delivery platform can significantly shorten development times and respond to virus mutations, and the NanoCherubTM Electric-Kinetic nanocomplex can consistently induce balanced and strong Th1/Th2 immunity against encapsulated antigens, including full pathogens, subunit proteins, peptides and messenger ribonucleic acid, with the added advantage of the vaccines only needing to be stored at 2°C to 8°C.
‧ Hepatitis B therapeutic vaccine completed in animal efficacy trials
Ascendo has also completed animal efficacy trials for its ASD253 vaccine for chronic hepatitis B. Following preclinical trials, Phase 1 human trials are to begin next year, when ASD253 is expected to become the world’s first vaccine for chronic hepatitis B.
The company also hopes to develop vaccines for HIV (AIDS), dengue fever, Zika and pan-influenza viruses.
Semiconductor shares in China surged yesterday after Reuters reported the US had ordered chipmaking giant Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) to halt shipments of advanced chips to Chinese customers, which investors believe could accelerate Beijing’s self-reliance efforts. TSMC yesterday started to suspend shipments of certain sophisticated chips to some Chinese clients after receiving a letter from the US Department of Commerce imposing export restrictions on those products, Reuters reported on Sunday, citing an unnamed source. The US imposed export restrictions on TSMC’s 7-nanometer or more advanced designs, Reuters reported. Investors figured that would encourage authorities to support China’s industry and bought shares
FLEXIBLE: Taiwan can develop its own ground station equipment, and has highly competitive manufacturers and suppliers with diversified production, the MOEA said The Ministry of Economic Affairs (MOEA) yesterday disputed reports that suppliers to US-based Space Exploration Technologies Corp (SpaceX) had been asked to move production out of Taiwan. Reuters had reported on Tuesday last week that Elon Musk-owned SpaceX had asked their manufacturers to produce outside of Taiwan given geopolitical risks and that at least one Taiwanese supplier had been pushed to relocate production to Vietnam. SpaceX’s requests place a renewed focus on the contentious relationship Musk has had with Taiwan, especially after he said last year that Taiwan is an “integral part” of China, sparking sharp criticism from Taiwanese authorities. The ministry said
CHANGING JAPAN: Nvidia-powered AI services over cellular networks ‘will result in an artificial intelligence grid that runs across Japan,’ Nvidia’s Jensen Huang said Softbank Group Corp would be the first to build a supercomputer with chips using Nvidia Corp’s new Blackwell design, a demonstration of the Japanese company’s ambitions to catch up on artificial intelligence (AI). The group’s telecom unit, Softbank Corp, plans to build Japan’s most powerful AI supercomputer to support local services, it said. That computer would be based on Nvidia’s DGX B200 product, which combines computer processors with so-called AI accelerator chips. A follow-up effort will feature Grace Blackwell, a more advanced version, the company said. The announcement indicates that Softbank Group, which until early 2019 owned 4.9 percent of Nvidia, has secured a
TECH SECURITY: The deal assures that ‘some of the most sought-after technology on the planet’ returns to the US, US Secretary of Commerce Gina Raimondo said The administration of US President Joe Biden finalized its CHIPS Act incentive awards for Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), marking a major milestone for a program meant to bring semiconductor production back to US soil. TSMC would get US$6.6 billion in grants as part of the contract, the US Department of Commerce said in a statement yesterday. Though the amount was disclosed earlier this year as part of a preliminary agreement, the deal is now legally binding — making it the first major CHIPS Act award to reach this stage. The chipmaker, which is also taking up to US$5 billion
RSS